The cancer drug developer emerged from stealth with $194m in funding, $85m of which was just closed in a round featuring returning investor Roche Venture Fund.
US-based precision oncology drug developer Black Diamond Therapeutics completed an $85m series C round yesterday that was backed by Roche Venture Fund, the corporate venturing subsidiary of pharmaceutical firm Roche.
The round was led by Boxer Capital and included Wellington Management, BVF Partners, Deerfield Management, Casdin Capital, Versant Ventures, New Enterprise Associates (NEA), Logos Capital, RA Capital Management, Nextech Invest, Invus, Perceptive Advisors, City Hill Ventures and funds managed by Janus Henderson Investors.
Founded in 2016 as Aset Therapeutics, Black Diamond is working on small molecule, tumour-agnostic treatments using its Mutation-Allostery-Pharmacology (Map) platform that will target cancer-causing mutations.
The technology is based on research co-developed by David Epstein, most recently vice-dean of innovation and entrepreneurship, and associate professor in cancer and stem cell biology, at Duke-NUS Medical School.
Epstein co-founded the company with Elizabeth Buck. The two had previously worked together at cancer drug producer OSI…
Thierry Heles
Thierry Heles is the editor of Global University Venturing, host of the Beyond the Breakthrough interview podcast and responsible for the monthly GUV Gazette (sign up here for free).
